Aspen Neuroscience Uses MRI-Guided ClearPoint Navigation System For Patients Enrolled In ASPIRO Phase 1/2a Clinical Trial For Transplantation Of Dopaminergic Neuron Precursor Cells In Patients With Parkinson's Disease
Portfolio Pulse from Benzinga Newsdesk
Aspen Neuroscience is using the MRI-Guided ClearPoint Navigation System for its ASPIRO Phase 1/2a clinical trial, which involves the transplantation of dopaminergic neuron precursor cells in patients with Parkinson's Disease.
June 20, 2024 | 12:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ClearPoint Neuro's MRI-Guided Navigation System is being used by Aspen Neuroscience in a clinical trial for Parkinson's Disease, potentially increasing demand and visibility for ClearPoint's technology.
The use of ClearPoint's Navigation System in a high-profile clinical trial can increase the system's visibility and credibility, potentially leading to higher demand and positive sentiment around CLPT.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80